A Study of Cabergoline for the Treatment of Cocaine Dependence - 1
This study has been completed.
Sponsor:
National Institute on Drug Abuse (NIDA)
Collaborator:
University of California, Los Angeles
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00033111
First received: April 5, 2002
Last updated: July 21, 2008
Last verified: July 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to assess cabergoline for the Treatment of Cocaine Dependence
| Condition | Intervention | Phase |
|---|---|---|
|
Cocaine-Related Disorders Substance-Related Disorders |
Drug: Cabergoline |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Phase 2, Double-Blind, Placebo Controlled Trial of Cabergoline for the Treatment of Cocaine Dependence |
Resource links provided by NLM:
Further study details as provided by National Institute on Drug Abuse (NIDA):
Primary Outcome Measures:
- New Use
- reduction of severity of cocaine dependence
| Estimated Enrollment: | 140 |
| Study Start Date: | June 2001 |
| Study Completion Date: | April 2004 |
To assess the efficacy and safety of cabergoline in reducing cocaine use in subjects with cocaine dependence. This is a DB, placebo-controlled, parallel group design study where subjects will receive either .5mg cabergoline or placebo for 12 weeks with a 4 week follow-up.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Must have a DSM-4 criteria for cocaine dependence; be seeking treatment for cocaine dependence; have the ability to understand and provide written informed consent; females of child-bearing potential using proper method of birth control.
Exclusion Criteria:
Additional criteria available during screening at the site.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00033111
Please refer to this study by its ClinicalTrials.gov identifier: NCT00033111
Locations
| United States, California | |
| Torrance Clinic | |
| Torrance, California, United States, 90502 | |
| United States, South Carolina | |
| Medical University of South Carolina | |
| Charleston, South Carolina, United States, 29425 | |
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
University of California, Los Angeles
Investigators
| Principal Investigator: | Steve Shoptaw, Ph.D. | Friends Research Institute, Inc. |
More Information
| ClinicalTrials.gov Identifier: | NCT00033111 History of Changes |
| Obsolete Identifiers: | NCT00024895 |
| Other Study ID Numbers: | NIDA-CTO-0007-1 |
| Study First Received: | April 5, 2002 |
| Last Updated: | July 21, 2008 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Disease Cocaine-Related Disorders Substance-Related Disorders Pathologic Processes Chemically-Induced Disorders Mental Disorders Cocaine Cabergoline Anesthetics, Local Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Sensory System Agents |
Peripheral Nervous System Agents Vasoconstrictor Agents Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Dopamine Agents Neurotransmitter Agents Antineoplastic Agents Antiparkinson Agents Anti-Dyskinesia Agents Dopamine Agonists |
ClinicalTrials.gov processed this record on September 29, 2016